0001683168-19-004036.txt : 20191219 0001683168-19-004036.hdr.sgml : 20191219 20191219161547 ACCESSION NUMBER: 0001683168-19-004036 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06c FILED AS OF DATE: 20191219 DATE AS OF CHANGE: 20191219 EFFECTIVENESS DATE: 20191219 FILER: COMPANY DATA: COMPANY CONFORMED NAME: KOP Therapeutics Corp. CENTRAL INDEX KEY: 0001793824 IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-353470 FILM NUMBER: 191295978 BUSINESS ADDRESS: STREET 1: SUITE 404 - 815 HORNBY STREET CITY: VANCOUVER STATE: A1 ZIP: V6Z 2E6 BUSINESS PHONE: 6047718332 MAIL ADDRESS: STREET 1: SUITE 404 - 815 HORNBY STREET CITY: VANCOUVER STATE: A1 ZIP: V6Z 2E6 D/A 1 primary_doc.xml X0708 D/A LIVE 0001793824 KOP Therapeutics Corp. SUITE 404 - 815 HORNBY STREET VANCOUVER A1 BRITISH COLUMBIA, CANADA V6Z 2E6 6047718332 BRITISH COLUMBIA, CANADA KOP Industries Ltd. None Corporation true 2018 Tibor Fancis Gajdics SUITE 404 - 815 HORNBY STREET VANCOUVER A1 BRITISH COLUMBIA, CANADA V6Z 2E6 Executive Officer Director Mark Richard Redcliffe SUITE 404 - 815 HORNBY STREET VANCOUVER A1 BRITISH COLUMBIA, CANADA V6Z 2E6 Executive Officer Director Marco Andres Strub SUITE 404 - 815 HORNBY STREET VANCOUVER A1 BRITISH COLUMBIA, CANADA V6Z 2E6 Director The proceeds will be used for research and development and general corporate and working capital purposes. Ian Hollis Mann SUITE 404 - 815 HORNBY STREET VANCOUVER A1 BRITISH COLUMBIA, CANADA V6Z 2E6 Director Biotechnology No Revenues 06c true 0001683168-19-003656 2019-10-22 false true true false 0 114000 114000 0 The two sales in the U.S. totaled $150,000 Canadian dollars. The Bank of Canada exchange rate on December 4, 2019, was 1 CAD = 0.76 USD. Accordingly, the Company received US $114,000. false 2 0 0 0 The proceeds will be used for research and development, and general corporate and working capital purposes. false KOP Therapeutics Corp. /s/ Tibor Gajdics Tibor Gajdics President 2019-12-19